What is HC Wainwright’s Forecast for BEAM FY2026 Earnings?

Beam Therapeutics Inc. (NASDAQ:BEAM) – Stock analysts at HC Wainwright issued their FY2026 earnings estimates for shares of Beam Therapeutics in a research report issued to clients and investors on Monday, February 3rd. HC Wainwright analyst P. Trucchio expects that the company will post earnings per share of ($3.30) for the year. HC Wainwright has a “Buy” rating and a $80.00 price target on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. HC Wainwright also issued estimates for Beam Therapeutics’ FY2027 earnings at ($3.00) EPS and FY2028 earnings at ($1.91) EPS.

Beam Therapeutics (NASDAQ:BEAM) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.01). The company had revenue of $14.30 million for the quarter, compared to the consensus estimate of $14.52 million. Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. The business’s revenue for the quarter was down 16.9% on a year-over-year basis. During the same period in the previous year, the business posted ($1.22) EPS.

BEAM has been the subject of several other research reports. Leerink Partnrs upgraded shares of Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 6th. Wedbush reaffirmed an “outperform” rating and set a $57.00 price objective on shares of Beam Therapeutics in a research report on Monday, January 13th. Scotiabank assumed coverage on Beam Therapeutics in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $24.00 target price for the company. Cantor Fitzgerald upgraded Beam Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Wednesday, January 29th. Finally, Sanford C. Bernstein upgraded Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 7th. Two research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Beam Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $47.67.

Beam Therapeutics Trading Up 0.6 %

Shares of NASDAQ BEAM opened at $25.75 on Wednesday. Beam Therapeutics has a twelve month low of $20.84 and a twelve month high of $49.50. The business has a 50 day simple moving average of $26.48 and a 200-day simple moving average of $25.76.

Hedge Funds Weigh In On Beam Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. ARK Investment Management LLC lifted its stake in shares of Beam Therapeutics by 8.2% in the 4th quarter. ARK Investment Management LLC now owns 7,068,029 shares of the company’s stock valued at $175,287,000 after purchasing an additional 536,930 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Beam Therapeutics by 21.7% during the fourth quarter. Bank of New York Mellon Corp now owns 276,917 shares of the company’s stock valued at $6,868,000 after buying an additional 49,372 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in shares of Beam Therapeutics in the fourth quarter worth about $330,000. Peregrine Investment Management Inc. bought a new stake in shares of Beam Therapeutics during the 4th quarter worth about $3,932,000. Finally, Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Beam Therapeutics by 11.4% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,957,611 shares of the company’s stock valued at $98,149,000 after acquiring an additional 404,782 shares during the last quarter. 99.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Beam Therapeutics

In other news, CEO John M. Evans sold 30,000 shares of the stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $26.75, for a total value of $802,500.00. Following the completion of the sale, the chief executive officer now owns 908,659 shares in the company, valued at $24,306,628.25. This represents a 3.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Christine Bellon sold 1,241 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $24.68, for a total transaction of $30,627.88. Following the sale, the insider now owns 102,968 shares of the company’s stock, valued at approximately $2,541,250.24. This represents a 1.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.20% of the stock is currently owned by insiders.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.